Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

What Didn't Happen in 2014: China Life Science IPOs

publication date: Jan 2, 2015
For lots of good reasons, 2014 was supposed to be a breakout year for China life science IPOs. As 2014 began, China was all set to resume IPOs after a 15-month moratorium, with a new regulatory system and significant pent-up demand. But, for the most part, the renaissance didn't happen. There was one very successful China pharma IPO in Hong Kong -- Luye Pharma staged a $764 million initial offering in July -- and iKang Healthcare came public in the US while Taicheng Pharma managed to wend its way through the China bureaucracy to list in Shenzhen. But that's a short list. What went wrong? More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here